Composition for gene editing and use thereof

Patent metadata

Field	Value
Publication number	US-2025002883-A1
Application number	US-202418758713-A
Country	US
Kind code	A1
Filing date	Jun 28, 2024
Priority date	Jun 29, 2023
Publication date	Jan 2, 2025
Grant date	—

Abstract

The present disclosure relates to a composition for gene editing and a use thereof. According to the present disclosure, an adenine base editor LbABE8e system in which a Cas12a protein variant including one or more mutations and adenine deaminase are fused has altered PAM specificity to achieve a significant genomic single base editing effect on target DNA, and thus expands the range of applicable CRISPR system selection. Accordingly, due to gene editing, it is expected that the adenine base editor LbABE8e system may be widely used in various fields, such as gene therapy, creation of commercial profits with industrial strains with improved productivity, improvement of the quality of public health care through improvement of intestinal microorganisms, and improvement of crops and livestock breeds free from GMO issues.

First claim

What is claimed is:

1 . A composition for gene editing comprising an adenine base editor in which a Cas12a protein variant including one or more mutations and adenine deaminase are fused; and guide RNA.

2 . The composition for gene editing of claim 1 , wherein the Cas12a protein variant includes one or more mutated amino acid residues corresponding to positions selected from the group consisting of amino acid positions of a wild-type Cas12a protein of 11, 12, 13, 14, 15, 16, 17, 34, 36, 39, 40, 43, 46, 47, 50, 54, 57, 58, 111, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 642, 643, 644, 645, 646, 647, 648, 649, 651, 652, 653, 654, 655, 656, 676, 679, 680, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 707, 711, 714, 715, 716, 717, 718, 719, 720, 721, 722, 739, 765, 768, 769, 773, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 871, 872, 873, 874, 875, 876, 877, 878, 879, 880, 881, 882, 883, 884, and 1048.

3 . The composition for gene editing of claim 2 , wherein the Cas12a protein variant includes one or more mutated amino acid residues corresponding to amino acid positions 532 and 595 of the wild-type Cas12a protein.

4 . The composition for gene editing of claim 3 , wherein the Cas12a protein variant includes mutated amino acid residues corresponding to amino acid positions G532R and K595R of the wild-type Cas12a protein.

5 . The composition for gene editing of claim 1 , wherein the Cas12a protein variant specifically recognizes PAM with a sequence TTCN compared to the wild-type Cas12a protein.

6 . The composition for gene editing of claim 5 , wherein the Cas12a protein variant specifically recognizes PAM with a sequence TTCC compared to the wild-type Cas12a protein.

7 . The composition for gene editing of claim 1 , wherein the Cas12a protein variant is derived from a bacterial species selected from the group consisting of Lachnospiraceae bacterium, Francisella novicid, Francisella tularensis, Prevotella albensis, Butyrivibrio proteoclasticus, Peregrinibacteria bacterium, Parcubacteria bacterium, Smithella sp., Acidaminococcus sp., Candidatus Methanoplasma termitum, Eubacterium eligens, Moraxella bovoculi, Leptospira inadai, Porphyromonas crevioricanis, Porphyromonas macacae, Succinivibrio dextrinosolvens, Prevotella disiens, Flavobacterium branchiophilum, Helcococcus kunzii, Eubacterium sp., Flavobacterium sp., Prevotella brevis, Moraxella caprae, Bacteroidetes oral, Porphyromonas cansulci, Synergistes jonesii, Prevotella bryantii, Anaerovibrio sp., Butyrivibrio fibrisolvens, Candidatus Methanomethylophilus, Butyrivibrio sp., Oribacterium sp., Pseudobutyrivibrio ruminis , and Proteocatella sphenisci.

8 . The composition for gene editing of claim 7 , wherein the Cas12a protein variant is derived from Lachnospiraceae bacterium.

9 . The composition for gene editing of claim 1 , wherein the adenine deaminase is derived from a bacterial species selected from the group consisting of Escherichia coli, Staphylococcus aureus, Salmonella typhi, Shewanella putrefaciens, Haemophilus influenzae, Caulobacter crescentus and Bacillus subtilis.

10 . The composition for gene editing of claim 9 , wherein the adenine deaminase is derived from Escherichia coli.

11 . The composition for gene editing of claim 1 , wherein the adenine base editor is any one selected from the group consisting of ABE8e, ABEmax, ABEmax-m, ABE8e-V106W, and ABE8.17-m.

12 . The composition for gene editing of claim 11 , wherein the adenine base editor is ABE8e.

13 . The composition for gene editing of claim 1 , wherein in the composition, adenine (A) is substituted with any one base selected from the group consisting of guanine (G), cytosine (C), and thymine (T).

14 . A gene editing method comprising contacting the composition for gene editing of claim 1 with a target sequence in vitro.

15 . A kit for gene editing comprising the composition for gene editing of claim 1 .

Assignees

• Univ Industry Cooperation Group Kyung Hee Univ
• Research & Business Found Sungkyunkwan Univ

Inventors

• Koo Taeyoung
• Kim Dae Sik
• Choi Eun Young
• Hwang Hye Yeon

Classifications

• C12N2310/20

  involving clustered regularly interspaced short palindromic repeats [CRISPR] · CPC title

• C12N15/113

  Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} · CPC title

• C12N9/78

  acting on carbon to nitrogen bonds other than peptide bonds (3.5) · CPC title

• C12N9/22 Primary

  Ribonucleases {[RNase]; Deoxyribonucleases [DNase]} · CPC title

• C12Y305/04001

  Cytosine deaminase (3.5.4.1) · CPC title